In the following video, Motley Fool health care analyst David Williamson talks about Pfizer's (NYSE:PFE) earnings report. He details how the company managed to cut costs and shore up emerging market sales -- leading to it beating expectations this quarter -- despite the loss of patent protection for its cardiovascular disease prevention drug Lipitor, which was once the greatest-selling drug of all time.
Jan 29, 2013 at 7:44PM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Motley Fool Returns
Stock Advisor S&P 500
5 Years 55% 38%
17+ years 346% 95%
Stock Advisor launched in February of 2002. Returns as of 11/20/2019.Join Stock Advisor